The news highlights the high efficacy of Seagen's Adcetris in combination with Nivolumab and standard chemotherapy for treating early-stage classical Hodgkin Lymphoma patients. This positive result may lead to increased demand for the drug, potentially boosting Seagen's revenues and stock price in the short term.